Key Takeaways
- The company’s adjusted EPS of $0.26 fell short of the $0.28 Wall Street consensus.
- Quarterly revenue increased 5% to $145.4 million, marginally exceeding projections.
- Fiscal 2027 revenue guidance of $664–$676 million significantly trailed the $697.4 million analyst consensus.
- Multiple firms including Jefferies, Wells Fargo, and KeyBanc downgraded their ratings on the stock.
- Shares declined approximately 21% in premarket activity Thursday and are down roughly 47% for the year.
Shares of Doximity were changing hands near $18.45 during premarket trading Thursday — representing a decline of approximately 21% from Wednesday’s closing price of $23.39 — following the company’s disappointing earnings report and underwhelming forward guidance that failed to meet Wall Street’s expectations.
The digital health platform announced adjusted earnings of $0.26 per share for the fiscal fourth quarter, falling short of the $0.28 consensus projection. This marked a decline from the $0.36 per share the company delivered in the comparable quarter last year.
Quarterly revenue reached $145.4 million, representing 5% year-over-year growth and marginally surpassing the $144 million analyst forecast. However, this minor revenue beat proved insufficient to calm investor concerns about the company’s future prospects.
Adjusted EBITDA for the period totaled $65.8 million, representing a 6% decline year-over-year, with management attributing the margin pressure primarily to elevated investments in AI infrastructure.
CEO Jeff Tangney highlighted robust platform engagement during the earnings conference call, revealing that more than 800,000 active prescribers utilized Doximity’s workflow solutions in Q4. “Approximately half of these healthcare providers leveraged our clinical AI capabilities last quarter, and our prompts per user nearly doubled between January and April,” Tangney stated.
Forward Outlook Disappoints Investors
The primary concern for market participants centered on the company’s guidance. For fiscal year 2027 ending March, Doximity projected revenue between $664 million and $676 million. This forecast came in substantially below the $697.4 million consensus estimate from analysts.
The first-quarter outlook similarly underwhelmed. Management forecast revenue of $151 million to $152 million, trailing the $153.7 million Street expectation.
Executives acknowledged that “near-term demand within the HCP digital pharma advertising market remains subdued” and cited macroeconomic uncertainty along with policy risks as factors clouding forward visibility. The company anticipates overall market expansion to remain muted, likely at or below the 5% level.
Adjusted EBITDA margin for fiscal 2027 is projected to come in around 49%, below historical levels, primarily driven by escalating AI compute expenses.
Wall Street Reacts with Downgrades
The earnings release prompted swift action from sell-side analysts. Jefferies downgraded the stock from Buy to Hold while slashing its price target from $51 to $19, citing limited visibility on pharmaceutical advertising budgets and mounting AI-related expenditures.
Wells Fargo lowered its rating from Overweight to Equal Weight, establishing a new price objective of $18. KeyBanc shifted to Sector Weight, observing that potential clients are increasingly evaluating AI-powered and more cost-effective alternatives to Doximity’s offerings.
Broader market strength provided no support. The S&P 500 advanced 0.58% while the Nasdaq climbed 1.20% on Thursday, indicating the DOCS selloff was purely company-specific.
DOCS now trades approximately 69% beneath its 52-week peak of $76.51. During the 90-day period preceding the earnings announcement, the stock experienced zero upward EPS estimate revisions against 15 downward adjustments — indicating sentiment was already deteriorating.
The company separately announced a strategic partnership with Aledade, a value-based care organization, through which Doximity will integrate its clinical AI tools, including documentation assistance and an AI-powered assistant, directly into Aledade’s platform.
